CCT2

Across TCGA pan-cancer cohorts, CCT2 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated CCT2 data layer compared with 3 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CCT2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CCT2 expression acts as an unfavorable survival marker, although some lineages such as READ and OV show a favorable association.

MESO, ACC, and LIHC are the cancer types where CCT2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.424	0.660	<.001	132	view →
ACC	OS	Median	All	0.773	0.963	<.001	125	view →
LIHC	DFS	Median	All	0.449	0.630	<.001	111	view →
LUAD	OS	Quartile	All	0.240	0.471	.001	72	view →
UVM	DFS	Median	III,IV	0.258	0.805	.001	68	view →
SARC	OS	Median	All	0.394	0.622	<.001	45	view →
HNSC	OS	Median	All	0.608	0.799	<.001	45	view →
KICH	OS	Quartile	II,III,IV	0.453	0.926	.006	38	view →
READ	DFS	Tertile	All	0.772	0.252	.005	28	view →
OV	OS	Median	III,IV	0.349	0.286	.027	18	view →
CESC	DFS	Quartile	IV	0.280	0.846	.005	16	view →
SCLC	OS	Median	II,III,IV	0.717	0.414	.005	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

CCT2–MESO (OS)

Open the MESO breakdown →